NeoGenomics, Inc.
$2.42B- Market cap
- $2.23B
- Debt
- +$341.86M
- Cash
- −$159.62M
Capital structure 87% equity / 13% debt · EV / Revenue 3.32x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt cap
Decision snapshot: NEO stock price at discount vs STE $17.38 current versus $20.88 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at STE's multiple
Implied fair value · at NEO's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: NEO FY 2025 (ended Dec 31, 2025) · STE FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 87% equity / 13% debt · EV / Revenue 3.32x
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 92% equity / 8% debt
STE carries the larger enterprise value at $23.83B against $2.42B; NEO trades on the lower EV / Revenue multiple (3.32x vs 4.01x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
NeoGenomics, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
STERIS plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.41x
0.27x
Net debt / EBITDA
Leverage against operating earnings
-4.48x
—
Cash and equivalents
Liquid reserves on the balance sheet
$159.62M
—
Total debt
Interest-bearing obligations outstanding
$341.86M
$1.93B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
NEO vs LH
QUEST DIAGNOSTICS INC
NEO vs DGX
OPKO HEALTH, INC.
NEO vs OPK
Guardant Health, Inc.
NEO vs GH
Natera, Inc.
NEO vs NTRA
EXACT SCIENCES CORP
NEO vs EXAS
Johnson & Johnson
NEO vs JNJ
BAXTER INTERNATIONAL INC
NEO vs BAX
BECTON DICKINSON & CO
NEO vs BDX
ZIMMER BIOMET HOLDINGS, INC.
NEO vs ZBH
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.